FDA Brief

Warning letters Drugs

FDA warning letter to

Zhejiang Huahai Pharmaceutical Co., Ltd.

High riskIssued Jun 6, 2025Posted Jun 17, 2025Office of Manufacturing Quality

FDA warns Zhejiang Huahai Pharmaceutical over CGMP violations including dirty equipment, aseptic-area tape, and data integrity issues.

What happened

FDA inspected the company’s finished-drug manufacturing facility from January 16 to 24, 2025. Investigators found residues of multiple active ingredients on non-dedicated equipment that records said had been cleaned, non-sterile tape and loose fittings in an ISO 5 aseptic area, and inadequate validation of tablet compression reject limits. They also observed a laboratory employee who appeared to approve environmental monitoring records non-contemporaneously.

What FDA found

  1. The company did not adequately clean non-dedicated manufacturing equipment; residues containing multiple active ingredients were found on surfaces recorded as cleaned.

    21 CFR 211.67(a)
  2. In an ISO 5 aseptic area, the company used non-sterile tape and had equipment that was not securely fastened, without informing the quality unit.

    21 CFR 211.42(c)(10)
  3. The company lacked adequate written production and process controls and validation data for tablet compression reject limits.

    21 CFR 211.100(a)
  4. A laboratory employee appeared to approve environmental monitoring records non-contemporaneously, raising concerns about data reliability.

What FDA wants

FDA asks the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, including comprehensive cleaning and contamination risk assessments, CAPA plans, and validation plans. FDA also recommends engaging a qualified CGMP consultant to audit the operation.

Who should pay attention

  • brands and distributors sourcing finished drugs from this site
  • patients taking prescription drugs made there
  • sterile drug manufacturers and contractors using aseptic processing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium